Vysis CLL FISH Probe Kit

For more information, contact Abbott.

Contact
Product Description
Results of Hybridization
Product Description

The Vysis CLL FISH Probe Kit is a test to detect deletion of the LSI TP53, LSI ATM, and LSI D13S319 probe targets and gain of the D12Z3 sequence probe target via fluorescence in situ hybridization (FISH) in peripheral blood specimens from patients with B-cell chronic lymphocytic leukemia (CLL) to aid in identifying those patients eligible for treatment with Venclexta® (venetoclax).

Vysis CLL FISH Probe Kit Contents

This kit contains five reagents sufficient to process 20 assays.

An assay is defined as one 22 mm x 22 mm Vysis LSI TP53 SpectrumOrange/ATM SpectrumGreen probe hybridization area and one 22 mm x 22 mm Vysis LSI D13S319 SpectrumOrange/13q34 SpectrumAqua/CEP 12 SpectrumGreen probe hybridization area.

Each kit includes:

  • Vysis LSI D13S319 SpectrumOrange/LSI 13q34 SpectrumAqua/CEP 12 SpectrumGreen Probes (1 vial, 200 µL/vial)

  • Vysis LSI TP53 SpectrumOrange/LSI ATM SpectrumGreen Probes (1 vial, 200 µL/vial)

  • DAPI II Counterstain (1 vial, 600 µL/vial)

  • NP-40 (2 vials, 200 µL/vial)

  • 20X Standard Sodium Citrate (SSC) Salt (1 bottle, 66 g)

  • Intended Use

    The Vysis CLL FISH Probe Kit is a test to detect deletion of the LSI TP53, LSI ATM, and LSI D13S319 probe targets and gain of the D12Z3 sequence probe target via fluorescence in situ hybridization (FISH) in peripheral blood specimens from patients with B-cell chronic lymphocytic leukemia (CLL).

    Indications For Use

    In untreated patients, the assay may be used to dichotomize CLL (the 13q-, +12, or normal genotype group versus the 11q- or 17p- group) and may be used as an aid in determining disease prognosis in combination with additional biomarkers, morphology, and other clinical information. The test is indicated for detecting deletion of the LSI TP53 probe target (17p-) as an aid in identifying those patients with CLL for whom treatment with VENCLEXTA® (venetoclax) is indicated. Vysis CLL FISH Probe Kit is not intended for monitoring of residual disease.

    The test is for prescription use only

    Limitations of the Procedure

    • When used to select CLL patients for treatment with VENCLEXTA® (venetoclax), the test is validated for peripheral blood specimens anticoagulated with sodium heparin only.
    • The Vysis CLL FISH Probe Kit is intended to be used in combination with additional biomarkers, morphology, and other clinical information.
    • Other signal patterns may occur, and metaphase analysis may be helpful in characterization of such patterns.
    • If a specimen has a low level abnormal FISH pattern, use of the appropriate single pass filter(s) to confirm the pattern is recommended. Failure to follow this recommendation may result in inaccurate identification of signal patterns.

    Rx Only

    For In Vitro Diagnostic Use

    To learn more about the Vysis CLL FISH Probe Kit please visit: https://www.molecular.abbott/us/en/products/oncology/vysis-cll-fish-probe-kit

    Results of Hybridization
    Each probe produces a single FISH signal for each copy of its target sequence.

    Hybridization of Vysis LSI TP53 SpectrumOrange/ATM SpectrumGreen Probes is expected to produce two orange p53 and two green ATM signals in cells with two normal copies of chromosomes 17 and 11.

    Hybridization of Vysis LSI D13S319 SpectrumOrange/13q34 SpectrumAqua/CEP 12 SpectrumGreen Probes is expected to produce two orange D13S319, two green CEP12, and two aqua LSI 13q34 signals in cells having two normal copies of chromosomes 12 and 13.

    Gains or losses of a specific probe target sequence will be observed as cells with either greater than or less than, respectively, two signals for that probe.

    While some abnormal CLL specimens are aberrant for only one probe locus, others may be abnormal for two or more loci. Other abnormal signal patterns may also occur.

    You are about to exit the Abbott family of websites for a 3rd party website

    Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

    Do you wish to continue and exit this website?

    Yes No

    You are about to enter an Abbott country or region specific website.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

    Do you wish to continue and enter this website?

    Yes No